Botulinum Toxin on Frey Syndrome: Who to Treat? Case Report and Literature Review
DOI:
https://doi.org/10.25759/spmfr.385Keywords:
Botulinum Toxins, Type A/therapeutic use, Sweating, Gustatory/drug therapyAbstract
Frey syndrome is mostly seen after parotidectomies and is an underdiagnosed surgical complication that may cause social inhibition and quality of life (QoL) deterioration. We report a case complemented with a literature review regarding the use of botulinum toxin on Frey syndrome. We consulted the patient’s file and photographed the Minor tests. We searched PubMed using the keywords: Frey syndrome; gustatory sweating; botulinum toxin. A 43-year-old woman, diagnosed with a pleomorphic adenoma of the left parotid gland treated by parotidectomy was referred to our Physical and Rehabilitation Medicine department due to symptoms suggestive of Frey syndrome: flushing and sweating on the left parotid region during meals with impact on socialization and QoL. Minor test confirmed the diagnosis. The patient underwent intradermic infiltration of 46U of onabotulinum toxin A (Botox®) across the positive area on Minor test that matched the patient’s complaints. Three weeks post-procedure, the patient denied hyperhidrosis (demonstrated on Minor test) and mentioned overall improvement on QoL. Treatment is symptomatic and should be offered to those patients whose symptoms cause a negative impact on QoL. Botulinum toxin infiltration is currently the gold standard treatment, since it is a safe, effective and reliable procedure. The Minor test is essential to optimise botulinum toxin dosage, thus reducing the possibility of occurring adverse effects.
Downloads
References
Lopes T, Barroso L, Mesquita M, Bitoque S, Lopez D, Ferreira A. Síndrome de Frey – Uma visão global do tema. Rev Port Estomatol Med Dent Cir Maxilofac. 2013; 54: 103-114. Portuguese. doi: 6210.1016/j.rpemd.2016. 02.002
Motz KM, Kim JY. Auriculotemporal Syndrome (Frey Syndrome). Otolaryngol Clin North Am. 2016 49: 501-9. doi: 10.1016/j.otc.2015.10.010.
Steffen A, Rotter N, König IR, Wollenberg B. Botulinum toxin for Frey’s syndrome: a closer look at different treatment responses. J Laryngol Otol. 2012; 126: 185-9. doi: 10.1017/S0022215111002581.
Gualberto GV, Sampaio FM, Madureira NA. Use of Botulinum toxin type A in Frey´s syndrome. An Bras Dermatol. 2017;92:891-2
Jansen S, Jerowski M, Ludwig L, Fischer-Krall E, Beutner D, Grosheva M. Botulinum toxin therapy in Frey’s syndrome: a retrospective study of 440 treatments in 100 patients. Clin Otolaryngol. 201;42:295-300. doi: 10.1111/coa.12719.
Downloads
Published
How to Cite
Issue
Section
License
Copyright statement
Authors must also submit a copyright statement (as seen below) on article submission.
To the Editor-in-chief of the SPMFR Journal:
The below signed author(s) hereby state that the article
________________________________________ (ref. MFR_________) is
an original unpublished work and all facts stated are a product of the author(s) investigation. This article does not violate any copyright laws or privacy statements. The author(s) also hereby confirm that there is no conflict of interest's issues in this article.
By submitting this article the author(s) agree that after publication all copyrights belong to the SPMFR Journal.
Signed by all authors
Date:
Names (capital letters):
Signatures:
The SPMFR Journal’s contents are follow a Creative Commons licence. After publication the authors can hand out the articles as long as the SPMFR Journal is credited.
